Ken Griffin Arcellx, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$49.74 - $66.98 $1.44 Million - $1.94 Million	-28,900 Reduced 93.23%	2,100 $115,000
Q1 2024 May 15, 2024	BUY	$51.85 - $73.49 $1.25 Million - $1.77 Million	24,100 Added 349.28%	31,000 $2.16 Million
Q4 2023 Feb 14, 2024	BUY	$31.75 - $57.99 $50,800 - $92,784	1,600 Added 30.19%	6,900 $382,000
Q3 2023 Nov 14, 2023	BUY	$31.51 - $37.4 $44,114 - $52,360	1,400 Added 35.9%	5,300 $190,000
Q2 2023 Aug 14, 2023	SELL	$27.49 - $46.9 $252,908 - $431,480	-9,200 Reduced 70.23%	3,900 $123,000
Q1 2023 May 15, 2023	BUY	$26.92 - $33.94 $75,376 - $95,032	2,800 Added 27.18%	13,100 $403,000
Q4 2022 Feb 14, 2023	BUY	$17.18 - $33.0 $176,954 - $339,900	10,300 New	10,300 $319,000

173

45.6M

53.6K

53.7K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.37B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.